EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases



Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases



European Journal of Endocrinology 139(3): 298-303



Stimulatory therapy with either GnRH or gonadotropins is an effective treatment to induce spermatogenesis and achieve paternity in men with secondary hypogonadism. However, there is still uncertainty about the optimal treatment modality and schedule, the duration of treatment necessary and the influence of interfering factors such as maldescended testes. We have extended our previous series of men treated for secondary hypogonadism and now present our therapeutic experience with 42 cases. Twenty-one patients with hypothalamic disorders (11 with idiopathic hypogonadotropic hypogonadism (IHH) and 10 with Kallmann syndrome (KalS)) were treated with GnRH (group Ia) or human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) (group Ib), and 21 patients with hypopituitarism (group II) were treated with hCG/hMG. A total of 5 7 treatment courses were initiated for induction of spermatogenesis, 36 of these for the purpose of induction of pregnancy in the female partner. Bilateral testicular volumes doubled within 5-12 months of therapy. Spermatogenesis as evidenced by the appearance of sperm in the ejaculate was induced in 54/57 courses. Pregnancies occurred in 26/36 courses. Unilaterally maldescended testes did not preclude patients with IHH or KalS from gaining fertility under therapy and spermatogenesis could be successfully initiated even in some individuals with bilateral maldescended testes. In general there was a tendency for a longer duration of therapy until induction of spermatogenesis in patients with a history of bilateral cryptorchidism. However, this did not reach statistical significance. In patients with IHH or KalS treated with either hCG/hMG or GnRH there were no statistically significant differences in terms of duration to appearance of sperm or pregnancy rates. Even in KalS patients as old as 43 years spermatogenesis could be induced. In repeatedly treated patients stimulation of spermatogenesis tended to be faster while time until induction of pregnancy was significantly shorter in the second treatment course. In conclusion, GnRH or hCG/hMG are effective therapeutic modalities for patients with IHH or KalS. It remains to be determined whether highly purified urinary gonadotropin preparations or recombinant LH and FSH will provide therapeutic advantages.

(PDF emailed within 0-6 h: $19.90)

Accession: 009275020

Download citation: RISBibTeXText

PMID: 9758439

DOI: 10.1530/eje.0.1390298



Related references

Gonadotropin or pulsatile GnRH as effective treatment for men with hypogonadotropic hypogonadism A review of 39 cases. International Journal of Andrology 20(SUPPL 1): 101, 1997

The testicular response to human chorionic gonadotropin and human chorionic gonadotropin human menopausal gonadotropin treatment in patients with hypogonadotropic eunuchoidism influence of endogenous fsh. Journal of Steroid Biochemistry 20(6 PART B): 1603, 1984

Testicular responsiveness to long term administration of human chorionic gonadotropin and human menopausal gonadotropin in patients with hypogonadotropic hypogonadism. Hormone Research (Basel) 23(1): 21-30, 1986

Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens. Journal of Clinical Endocrinology and Metabolism 61(4): 746-752, 1985

The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization. Clinical Endocrinology 88(1): 77-87, 2017

Comparative cost and clinical effectiveness of pulsatile gonadotropin releasing hormone and human menopausal gonadotropin therapy for infertile women with hypogonadotropic hypogonadism. Journal of Endocrinology 111(SUPPL), 1986

Pulsatile gonadotropin releasing factor treatment in azoospermic patients who previously failed human menopausal gonadotropin human chorionic gonadotropin treatment. Journal of Endocrinological Investigation 8(SUPPL 3): 173, 1985

Pulsatile GnRH and/or gonadotropin treatment of men with idiopathic hypogonadotropic hypogonadism. Hormone Research (Basel) 53(Suppl 2): 86, July, 2000

Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: the response to human chorionic gonadotropin is predicted by initial testicular size. Journal of Clinical Endocrinology and Metabolism 66(6): 1144-1151, 1988

Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. Journal of Clinical Endocrinology and Metabolism 94(3): 780-785, 2008

Preliminary report about a modified gonadotropin (human menopausal gonadotropin/human chorionic gonadotropin) treatment in infertile patients with premature luteinization. Fertility and Sterility 41(5): 714-718, 1984

Combined human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) treatment in gonadotropin-deficient males with pituitary dwarfism. Acta Paediatrica Japonica 34(2): 243-8; Discussion 249-50, 1992

The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty. European Journal of Endocrinology 149(1): 23-29, 2003

A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism. Reproductive Medicine and Biology 9(1): 57-60, 2010

A successful conception by a shift from human menopausal gonadotropin therapy to therapy with recombinant human follicular-stimulating hormone for the treatment of male hypogonadotropic hypogonadism. Reproductive Medicine and Biology 9(1): 57-60, 2018